This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cryz, S J Articles by Germanier, R Search for Related Content PubMed PubMed Citation Articles by Cryz, S J, Jr Articles by Germanier, R

 Previous Article  |  Next Article 

Infect Immun. 1983 May; 40(2): 659-664

Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model.

ABSTRACT

An experimental leukopenic mouse model was used to evaluate the protective capacities of immunoglobulin G (IgG) fractions directed against toxin A (AT-IgG), elastase (AE-IgG), and lipopolysaccharide (ALPS-IgG) against fatal Pseudomonas aeruginosa infection. Statistically significant protection, as measured by long-term survival, was observed only when mice were treated with serotype-specific ALPS-IgG. The mean lethal dose for P. aeruginosa could be increased by as much as 6,600-fold for mice given ALPS-IgG as compared to mice which received only normal rabbit IgG. ALPS-IgG afforded high levels of protection, even when administered up to 6 h postchallenge. Experiments designed to monitor the growth and spread of a locally administered challenge showed that ALPS-IgG prevented bacteremia and organ colonization, which were pronounced in control animals. The effectiveness of combined antibiotic and immune therapy was tested. Gentamicin alone or in combination with AT-IgG or AE-IgG provided no detectable protection. However, its use with ALPS-IgG afforded substantially higher levels of protection than ALPS-IgG alone.

This article has been cited by other articles:

• Scarff, J. M., Goldberg, J. B. (2008). Vaccination against Pseudomonas aeruginosa Pneumonia in Immunocompromised Mice. CVI 15: 367-375 [Abstract] [Full Text]  
• Park, I. H., Youn, J. H., Choi, I.-H., Nahm, M. H., Kim, S. J., Shin, J.-S. (2005). Anti-Idiotypic Antibody as a Potential Candidate Vaccine for Neisseria meningitidis Serogroup B. Infect. Immun. 73: 6399-6406 [Abstract] [Full Text]  
• Koh, A. Y., Priebe, G. P., Pier, G. B. (2005). Virulence of Pseudomonas aeruginosa in a Murine Model of Gastrointestinal Colonization and Dissemination in Neutropenia. Infect. Immun. 73: 2262-2272 [Abstract] [Full Text]  
• Priebe, G. P., Meluleni, G. J., Coleman, F. T., Goldberg, J. B., Pier, G. B. (2003). Protection against Fatal Pseudomonas aeruginosa Pneumonia in Mice after Nasal Immunization with a Live, Attenuated aroA Deletion Mutant. Infect. Immun. 71: 1453-1461 [Abstract] [Full Text]  
• Hemachandra, S., Kamboj, K., Copfer, J., Pier, G., Green, L. L., Schreiber, J. R. (2001). Human Monoclonal Antibodies against Pseudomonas aeruginosa Lipopolysaccharide Derived from Transgenic Mice Containing Megabase Human Immunoglobulin Loci Are Opsonic and Protective against Fatal Pseudomonas Sepsis. Infect. Immun. 69: 2223-2229 [Abstract] [Full Text]